Overview

Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)

Status:
Completed
Trial end date:
2019-09-06
Target enrollment:
Participant gender:
Summary
Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)
Phase:
N/A
Details
Lead Sponsor:
Geropharm
Treatments:
Darunavir